Avidity Plans Spin-Off Amid Novartis Acquisition Agreement

The latest update is out from Avidity Biosciences ( (RNA) ).

On February 2, 2026, Avidity Biosciences announced that its board has set February 12, 2026, as the expected record date for a pro rata spin-off of Atrium Therapeutics (SpinCo), distributing one share of SpinCo common stock for every ten Avidity shares held, in connection with Novartis AG’s proposed acquisition of Avidity and the carve-out of Avidity’s early-stage precision cardiology programs into the new entity. Completion of both the Novartis merger and the SpinCo spin-off remains contingent on customary closing conditions, including shareholder and regulatory approvals, meaning the record date could still change, and leaving investors focused on execution risk, transaction timing and the future alignment of Avidity’s remaining RNA therapeutics portfolio versus the standalone cardiology-focused SpinCo.

The most recent analyst rating on (RNA) stock is a Hold with a $72.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.

Spark’s Take on RNA Stock

According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.

The overall stock score reflects a mix of strong technical momentum and positive corporate events, particularly the merger with Novartis, which is a major strategic development. However, financial performance challenges, including negative profitability and cash flow, weigh on the score. The valuation reflects typical biotech growth characteristics, with a focus on future potential rather than current earnings.

To see Spark’s full report on RNA stock, click here.

More about Avidity Biosciences

Avidity Biosciences is a San Diego-based biopharmaceutical company focused on a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs), which combine monoclonal antibody specificity with oligonucleotide precision to target diseases previously unreachable with existing RNA therapies. Leveraging its proprietary AOC platform, the company is developing clinical programs for rare muscle diseases, including myotonic dystrophy type 1, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy, while also advancing precision cardiology candidates for rare genetic cardiomyopathies and expanding its pipeline in cardiology and immunology through partnerships.

Average Trading Volume: 2,500,327

Technical Sentiment Signal: Buy

Current Market Cap: $10.94B

See more data about RNA stock on TipRanks’ Stock Analysis page.